Skip to content
Business websites
Business websites
Johnson & Johnson
J&J MedTech
Johnson & Johnson
J&J MedTech
Location
Language
English
Choose your local market.
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
India
English
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
Menu
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Newsroom
The latest news, information, and stories from Johnson & Johnson Innovative Medicine.
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
272 Results
272 Results
Open
Filters
Sort By
Newest
Newest
Relevance
Oldest
Oncology
Early results from Johnson & Johnson’s trispecific antibody show promising response in heavily pretreated multiple myeloma patients
June 3, 2025
Read more
Oncology
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
June 3, 2025
Read more
Oncology
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
June 3, 2025
Read more
Oncology
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-mutated mCSPC
June 3, 2025
Read more
Oncology
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
June 1, 2025
Read more
Oncology
Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA
May 22, 2025
Read more
Oncology
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
May 21, 2025
Read more
Immunology
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
May 9, 2025
Read more
Immunology
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
May 5, 2025
Read more
Immunology
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
May 5, 2025
Read more
1 of 28
Next
Featured stories
Connecting the best of Health&Care
Read more
Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list
Read more
The power of precision medicine for patients
April 25, 2024
Gabriele Alegri
Read more
What is a gene mutation?
Read more
